thought
view around room outlook
turn toward grid upgrad neutral under-perform rais estim target price
data impact valrox opportun rais target price
enough updat lower estim rais target price
soundbit convers manag
 buy dip
weekli check-up staf specialti svc outperform week statu mltss program adopt
hemophilia gene therapi hem gene therapi pois go prime-time
firework continu put risk adjust program hold thought
justif worri
ppi ex food energi mom jun
ppi ex food energi yoy jun
ny fed presid speak
busi commun leader
cpi ex food energi mom jun
cpi ex food energi yoy jun
analyst disclosur credit suiss seek busi compani cover research
report result investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest
 mich sentiment jul prelim cs
polici report congress ahead
chair powel testimoni juli
receiv product pleas specifi credit suiss contact email call
thought
contrast econom market move togeth year contradict
diverg mid-year report focus tailwind move stock forward headwind hold back
 econom data continu show sign strength expect grow year
time concern around inflat tighten monetari polici potenti trade war weigh
incom data point upsid
recent econom report encourag ism read sign robust expans latest
job report homerun payrol particip increas wage pressur moder
 global trend diverg
describ global synchron recoveri year region diverg recent
month econom surpris lead indic remain strong roll abroad diverg
also evid corpor profit interest rate differenti
ytd return mix bag stock ralli early-januari declin sharpli late-januari early-
februari advanc sinc factor perform follow suit pro-cycl characterist earn
growth revis lead expansionari period
view around room outlook
hood
leverag breadth depart report identifi theme pattern driver across sector
industri addit analyst identifi top idea lever theme focu name
remaind year
thought
contrast econom market move togeth year contradict
diverg mid-year report focus tailwind move stock forward headwind hold back
 econom data continu show sign strength expect grow year
time concern around inflat tighten monetari polici potenti trade war weigh
incom data point upsid
recent econom report encourag ism read sign robust expans latest
job report homerun payrol particip increas wage pressur moder
 global trend diverg
describ global synchron recoveri year region diverg recent
month econom surpris lead indic remain strong roll abroad diverg
also evid corpor profit interest rate differenti
ytd return mix bag stock ralli early-januari declin sharpli late-januari early-
februari advanc sinc factor perform follow suit pro-cycl characterist earn
growth revis lead expansionari period
receiv product pleas specifi credit suiss contact email call
turn toward grid upgrad neutral under-perform rais estim target price
larg project defeat programmat spend ahead defeat year propos northern
pass transmiss project sever larg off-shore wind solicit see strateg turn develop toward
steadi capit growth grid modern pipe replac electr transmiss project possibl discuss
call under-perform sinc jan upgrad neutral stock total return potenti
next month
like maintain long-term ep guidanc concern compani abil keep
guidanc intact without northern pass stock buy-back see enough lower-risk programmat capit growth
support midpoint without share repurchas specif expect compani develop file grid
modern program connecticut complement track mechan approv recent cl rate
order massachusett latest nstar rate order approv grid modern tracker plu
batteri storag electr vehicl infrastructur follow plan yanke ga
recent rate file includ three-year pipe replac propos mostli ct aquarion
water alreadi ramp annual capital-expenditure expect grow four year
estim valuat rais estim respect assum
addit placehold capital-expenditure hit compound-annual-growth-rate still guidanc midpoint rais tp
base averag peer electr ga p/e premium transmiss risk includ outcom
state rate review transmiss roe project approval/execut
data impact valrox opportun rais target price
remain posit first mover hemophilia gene therapi convent wisdom suggest investor
focu compound first best valrox continu hold year lead market nearest
competitor think time market uniformli determin success hem gene therapi
signific clinician feedback suggest lt safeti durabl effect key arbit uptak along
gene tx achiev fviii express elimin risk spontan bleed suspect could take sever
year evidence-bas assess made best therapi differenti success
product may subtl
construct updat reflect base model expect deliv data carv path
studi hem market build assum success gene therapi product market
alloc lt market share upsid monopoli scenario
think spark upcom data month exposur like allow winner declar see larger
long-term dataset necessari fulli determin product variabl base share assumpt
differenti less express variabl lower need steroid lt safety/dur take year defin
product first mover consider advantag robust lt data
rais tp outlin today hemophilia note see robust hem gene therapi market
driven high patient demand global opportun grow argument gene therapi uptak emerg
market tp increas reflect moder expand gene therapi market view patient estim
treat global total hem patient global risk thesi includ clinic regulatori
commerci headwind
receiv product pleas specifi credit suiss contact email call
enough updat lower estim rais target price
grow comfort lt outlook viabil ahead updat management consist
messag gene therapi target product profil includ patient achiev fviii activ level elimin
spontan bleed risk without exceed mean normal level parallel compani repeatedli
confirm current contempl higher dose cohort beyond current peak dose find
reassur viabl go-forward dose level like identifi on-going believ spark
like second hem gene therapi valrox move studi
hard time develop high convict either way short-term stock move recent rise spark
share reflect high optim continu see upsid potenti tp nt best-cas data
patient mean express approx think risk outright flop quit low defin
dose group test viabil potenti downsid scenario construct data even minor
perceiv flaw mean express low end target rang elong plans/ne evalu higher dose
group exampl could pressur share anywher near-term make call lt durabl intra-
dose variabl seem like fool errand month data patient like opin along
rest street data becom avail
valuat reflect heighten expect reiter outperform rais tp expect
construct updat elev alreadi high specul around spark hem remain larg competit
market annual sale think may becom like de-risk space spark
biomarin other dataset continu accru matur increas tp reflect elev premium
increas po row market assumpt revenu risk thesi
commerci clinical/regulatori
bottom line mu confirm fuzhou intermedi peopl court fujian provinc china notifi two
chines subsidiari mu grant preliminari injunct entiti patent infring case
fill umc jinhua preliminari injunct prohibit mu chines subsidiari manufactur sell
import certain dram modul ssd china magnitud impact modest fear
total china vs mu ship-in china total mu reiter within
guid rang despit impact unfavor nt event would highlight
consid real potenti given histori speedi somewhat bias rule remov headlin
risk weigh stock continu agre mu umc/jhic claim without merit
almost meaningless slap wrist china court suggest current us/china trade disput
constrain china court fear escal -- signific albeit low probabl embargo us
sce tool necessari china domest semi plan
litig background tw file indict umc mu file lawsuit umc/jinhua court
-- umc file countersuit note chines court tend rule quickli
region -- note mu commentari fuzhou court issu rule allow mu opportun present
re-affirm guidanc mu reiter within guid rang despit impact
continu view midpoint guidanc conserv even account impact bit
growth target dram/nand impli rev/gm/ep alreadi track high-end guidanc
re-affirm lack merit mu continu argu patent invalid mu product infring patent
-- state patent direct technolog previous develop patent countri
compani situat escal would rule place restrict sce sale
receiv product pleas specifi credit suiss contact email call
bottom line friday announc complet acquisit cavm follow china regulatori approv
also announc sy ali co-found ceo cavm brad buss cfo solar citi
cfo cypress semi dr edward frank vice-president hw engin vice-president
appoint board director comment
financi impact note cavm embed rev/ep guidanc
cavm end juli impli potenti upsid acceler
accret cost synergi realiz continu argu ep accret versu manag
guidanc cost synergi within month accret addit expect least
synergi explicitli outlin management impli ep least much vs
current ep street would highlight
rev/ep expect expect rev/ep guidanc
emb cavm -- reflect cavm opm adjust share issu
financ transact
china dynam concern mchp/mscc mrvl/cavm rel us/china regulatori
dynam -- deal approv timefram initi outlin along pend zte resolut
guidelin provid comfort us/china dynam
valuat compel trade ev/fcf vs semi account cavm accret
fcfp -- tp impli pf ev/fcf w/sbc in-line semi believ
justifi base transform natur acquisit
fed payment survey review recent releas feder reserv survey consum
payment choic find encourag trend usag fund method
usag increas account holder report make payment paypal increas
view indic expand market penetr improv brand strength
note top download financi app
fund method diversifi predominantli ach ach far use fund sourc payment
credit next common note fund method increas suggest choic initi
help diversifi fund mix oppos channel fund sourc credit fear
find expect broad payment trend larg line would expect stabl cash use
slight increas credit slight decreas debit statist signific declin check use on-line payment
continu expand total non-bil payment total retail purchas
soundbit convers manag
view amzn-pillpack announc recent caught manag varieti topic
respect amazon-pillpack announc note pillpack part compani network repres
insignific amount pbm busi point pbm model driven promot one particular
fulfil option mandatori mail order say would will credenti mail-ord pharmaci
retail pharmaci whole food amzn/brk/jpm new ceo dr atul gawand flag
dr gawand write-up favor highlight wellm optum subsidiari focu reduc cost
reduc expens unnecessari care reward doctor base cost save provid long-term care
optimist environ remain optimist environ see decis
reinstat open enrol period oep allow one-tim enrol elect begin
consist agenc focu consumer believ market much differ
last time oep place see oep reinstat signific impact market
overal fact given high qualiti net promot score np might modest posit compani
comment pbm sell season respect pbm sell season agre thesi
pbm rfp activ year rel low number key player go transit
cvs/aet ci/esrx howev compani highlight optumrx contract three region
health plan thu far
receiv product pleas specifi credit suiss contact email call
homebuild homebuild stock coverag end week rel quiet week
builder given juli holiday june minut releas thursday offici gener note us
econom strength indic gradual rate hike consist medium-term object notabl
committe state residenti mortgag financ condit remain accommod borrow rate still
low compar histor level member also comment rise labor cost compani face persist
labor shortag particularli among skill worker turn concern express escal global trade risk
outperform rate name includ
build product build product group end week led come appoint
new ceo yuval dagim morn start date announc shortli yair averbuch took role
interim basi march depart previous announc note mr dagim background includ success around
global suppli chain process well market consum base product construct oper
view well suit compani continu fulli ramp product yield us facil work
recent issu isra oper improv market distribut strategi us also recent
host meet leggett ceo ir convers focus opportun within bed auto
well steel inflat support macro backdrop demand remain intact across compani end market
geographi respons rise cost continu pursu price across mani largest busi although
came away encourag path ahead believ near-term result like remain pressur price
catch inflat highlight outperform rate
us natur ga fall despit libya declar forc majeur load zueitina hariga
port bring countrywid suppli disrupt mbbld report opec oil product held rel flat
mom june despit larg increas saudi arabia declin crude came
pressur due on-going comment us presid trump pressur opec rais output order lower price
unexpect build us crude stock mix headlin saudi product last month rang
mbbld mom increas natur ga fell nearli entir weekli drop occur
monday despit outlook above-averag temperatur
 ps under-perform broader market xop under-perform
univers oil-weight ps averag rose permian name bakken name
compani news host investor meet apc manag walk away even confid
stock particularli given belief increas share buy-back program like attract econom
mozambiqu project think reflect stock price announc secur new five-year
sale agreement delawar basin oil product transport gulf coast mbbld begin juli
increas mbbld begin octob includ prior transport agreement hedg estim
mbbld companywid oil volum expos widen basi permian
epic pipelin commenc announc two separ transact bp sell
stake uk clair field retain interest simultan acquir bp interest greater
kuparuk area alaska boost total stake project transact price disclos
deal expect cash neutral compani disclos fire broke tank batteri glasscock
counti impact shut-in product expect bbld consensu estim
reiter total oil product guidanc icahn increas ownership egn combin
corvex/icahn ownership share outstand armi corp seem reinstat mvp permit
river cross west virginia court-issu stay remain effect
look week ahead eia disclos short term energi outlook tuesday opec iea disclos
monthli oil market report updat s/d forecast wednesday thursday respect
expect eia report bcf storag inject thursday
receiv product pleas specifi credit suiss contact email call
 buy dip
refin trade sideway week refin under-perform market
energi doubt us refin great posit busi gener lot
cash best manag team energi industri run show
independ refin today refin capac ever control past us independ
refin gone empir build activ taken market share global major global
independ refin posit perfectli benefit approach imo driven refin upcycl
reason also tempt issu buy dip call howev would let screen determin
call vs invest process develop help us correctli predict time pullback
prime reason hold buy dip call market underestim risk cush inventori
deplet cush crude inventori level last year averag cush draw
acceler last week delay start-up syncrud tighten balanc cush
crude inventori dip mmbl tank bottom challeng pull crude cush put sever
pressur brent-wti spread current pace draw continu real risk cush hit tank bottom
padd turnaround commenc neg revis fulli factor stock current street
estim averag estim base current crack compress key diff
earn could believ market still optimist time rebound crack
would help avoid neg near-term earn revis expect refin trade sideway upcycl
resum late august earli septemb
crack mix major crack wc gc mid-west nyh flat mid-con
gasolin crack gc mid-con mid-west nyh distil crack
mix gc mid-west mid-con nyh wc
diff mix brent-wti narrow wti-wc narrow brent-ll
narrow midland-cush widen major tailwind dk
believ cush constrain permian take-away remain major concern expect diff blow-out
within coverag under-perform andv outperform
top question week impact scott pruitt leav epa rin price
weekli check-up staf specialti svc outperform week statu mltss program adopt
medic staf specialti servic outperform week end juli coverag average
outperform under-perform broader hc sector hcx medic staf
specialti servic perform best death hospit under-perform
outperform lpnt under-perform
perform best last week lpnt md perform worst last week
 week statu mltss program adopt macpac june report congress medicaid
chip organ look statu state adopt area program evolut manag long-term
servic support mltss bln roughli medicaid ltss spend mltss program
roughli mln individu enrol mltss program use mltss medicaid grown substanti
recent year jan state mltss program compar eight state jan
state differ mltss program mltss expect continu evolv exist program matur
state transit mltss instanc eight state offer mltss program individu intellectu
develop disabl i/dd howev state reluct pursu mltss exampl state law prohibit
indiana medicaid program implement mltss
valuat major mco trade ep estim ci least expens price-to-earnings hospit
trade ebitda
receiv product pleas specifi credit suiss contact email call
hemophilia gene therapi hem gene therapi pois go prime-time
magnitud hemophilia gene therapi opportun remain debat believ gene therapi could becom
foundat approach hemophilia manag look updat summer spark sangamo/pf
hem increment evolv landscap
sign high patient demand exist underappreci cost-benefit emerg market opportun possibl
sourc upsid rapid enrol patient accru clear sign
demand think compel argument bearish view current hem treatment adequ
risk gene therapi high patients/clinician also see substanti evid suggest lt argument
favor gene therapi uptak emerg market outcom poor result on-demand treatment lower-
dose prophylaxi use think hem gene therapi could cost-effect address popul
forecast uptak hem increasingli look binari us lt safeti durabl comfort
establish year post gene therapi launch anticip broad adopt gene therapi given conveni
econom benefit either big bad unknown materi durabl disappoint median effect
year less lt safeti signal present think uptak would ultim disappoint greatli base
assumpt anticip total us hem popul treat pt global
estim commerci address global popul potenti consider upsid bull scenario
lt safeti clean durabl exce expect re-dos becom realiti manag potenti wane
efficaci time improv cost-effect treatment gene therapi expand address global popul
vs investor debat may miss point investor convers often end debat
winner split first-to-market best peak effect higher consistency/reduc
variabl among kol convers featur adher real market sign back
reduc factor viii variabl would ideal meanwhil phase strong enrol trend speak loudli lt
safety/dur databas ahead ultim think confirm durabl lt safeti gate
issu uptak intermedi term market view suggest two even three hem product may
commerci viabl lt base clinic patient prefer global commerci reach
launch disrupt hem asset base scarciti valu hem gene tx asset number larg compani
invest hemophilia recent preced hemophilia think subtl commerci differenti argument
like settl eventu acquir lead gene therapi asset
take -- renew sector sunni project win global appreci impact ir
tax credit safe harbor rule project develop regulatori newsflow understand quieter juli
week modul manufactur continu face glut face spot modul price declin anoth week
ytd also dissect new batteri storag project ca seem line last month nevada rfp
take -- util illustr integr util lag somewhat stronger regul
out-performance flight safeti amid trade-war induc market volatil note larg cap especi
emphas morn within cs mid-year outlook continu favor integr rise rate
environ especi regul util begin under-perform revers discount price-to-earnings
base histor correl treasuri yield
date juli host meet util regul naruc summer polici confer
phoenix arizona pleas contact us sale rep detail
receiv product pleas specifi credit suiss contact email call
firework continu put risk adjust program hold -- thought
temporarili halt risk adjust program juli announc temporarili halt
afford act risk adjust program cite late feb new mexico district court decis found formula
calcul risk adjust payment flaw nm district court rule current bar collect
make payment current methodolog use statewid averag premium ask court
reconsid rule hope prompt resolut note releas provid addit guidanc
shortli handl relat issu includ appeal risk adjust amount roughli bln
total expect releas final plan year risk adjust summari report accompani issuer transfer
anoth sourc uncertainti like impact mco approach risk adjust one three
perman rest two expir post risk adjust program individu small group
market zero sum game transfer fund plan rel healthi enrolle plan rel sick
enrolle program primari goal encourag insur sign broad consum base instead target
young healthi peopl risk-adjust transfer repres total premium dollar individu
market futur risk adjust program uncertain particip insur reassess
compliant small group individu market approach believ could also discourag potenti new
market entrant next year would risk adjust program fall back case advers plan
public mco net payabl posit among public mco aet mln ci mln mln
mln pro-forma fide mln net risk adjust payabl posit plan year
ci mln mln mln book addit payabl plan year
suspens risk adjust program year would signific posit compani
drop payment relat year like seen prior period adjust program termin
would impli potenti upsid current expect undisclos risk adjust receiv
plan year might write-off amount program uncertainti persist refer receiv
mln risk adjust plan year receiv mln risk adjust essenti exit
individu market
uncertainti blue blue histor risk adjust receiv posit given broader network
attract offer thu appeal rel broader risk level enrolle fact base analysi
plan year major non-anthem blue receiv risk adjust payment individu small group market
health servic corpor mln bcb michigan mln shield ca mln bcb florida
mln etc futur risk adjust program limbo risk lose plan year relat
collect blue might reassess approach individu small busi market believ
allay on-going fear around competit blue price next year fact bcb associ alreadi
note risk-adjust issu resolv soon would significantli increas premium individu
small group market could result far fewer health plan choic
implic hospit neutral slightli neg hospit healthcar provid directli
impact risk adjust program chang could destabil marketplac repres modest
risk group risk adjust program termin particip health insur like gravit
toward moh-lik strategi limit coverag narrow network might ideal
reimburs scenario hospit perspect estim benefit relat hix repres less
ebitda exposur less exposur lpnt
receiv product pleas specifi credit suiss contact email call
justif worri
cs larg cap bank group begin report second quarter earn morn juli jpmorgan
weigh first expect industri fundament solid fairli consist
mid-quart updat loan growth invest bank revenu gener acceler june enough
yield curv shift support modest nim expans even pace deposit growth unchang slow competit
intensifi trade revenu forecast unchang june look bit better low credit cost remain posit
one expect loss rate remain low equiti price weak unwelcom element forecast
ep year-over-year respect averag rote quarter fine
forward look earn growth return prospect tie macro support clariti respect regulatori reform
larg cap bank ep expect increas yr/yr qtr/qtr consensu yr/yr
exclud benefit tax reform note still quit healthi growth pre-tax incom expect increas yr/yr
mid cap bank ought put similarli strong comparison impli expect yr/yr qtr/qtr
revenu growth oper leverag realiz low credit cost drive comparison underpin
yr/yr qtr/qtr revenu growth forecast modest nim expans tie yield curv shift ii pick
pace loan growth slower deposit growth manifest unevenli volum price perspect iii
trade revenu comparison yr/yr sequenti reflect typic season invest bank regain
momentum end quarter sequenti industrywid expect larg cap bank effici ratio
averag improv yr/yr respect credit estim emb sequenti higher
credit cost loss rate migrat higher net addit rather deplet loan loss reserv
watch loan deposit price liquid deploy deposit growth slow latter increas
potenti intens competition/acceler deposit beta ii uptick financ demand-consum loan growth
 loan growth capit market activ iii capit market prospect -- invest bank pipelin recal goldman
comment record pipelin late may outlook trade revenu iv oper leverage/invest
spend credit qualiti migrat vi regulatori reform-new ccar/capit requir volcker rule reform
cecl focu
receiv product pleas specifi credit suiss contact email call
headlin price previou day close unless otherwis note
compani mention price jul
